MedTrace Logo

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

NCT02258217 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-09-01

Study results available
· View outcomes & findings →

Summary

Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Acthar

Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.

Sponsors & Collaborators

  • OhioHealth

    lead OTHER

Principal Investigators

  • Aaron L Boster, MD · OhioHealth

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-06-24
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02258217 on ClinicalTrials.gov